A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapsed/Refractory Multiple Myeloma

2023-508426-10-00 Protocol 64007957MMY1008 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 3 Jun 2024 · Status Ongoing, recruitment ended · 5 EU/EEA countries · 29 sites · Protocol 64007957MMY1008

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 100
Countries 5
Sites 29

Relapsed/Refractory Multiple Myeloma

Key facts

Sponsor
Janssen Cilag International
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Hemic and Lymphatic Diseases [C15]
Trial duration
3 Jun 2024 → ongoing
Decision date (initial)
2024-06-03
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Relapsed/Refractory Multiple Myeloma

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen Cilag International

Sponsor organisation
Janssen Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Locations

5 EU/EEA countries · 29 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruitment ended 10 4
Germany Ongoing, recruitment ended 10 4
Italy Ongoing, recruitment ended 10 6
Poland Ongoing, recruitment ended 9 7
Spain Ongoing, recruitment ended 9 8
Rest of world
Korea, Republic of, Australia, Canada, United States, United Kingdom
52

Investigational sites

France

4 sites · Ongoing, recruitment ended
Hospices Civils De Lyon
Hematology Department, 165 Chemin Du Grand Revoyet, 69310, Pierre-Benite
Centre Hospitalier Universitaire De Lille
Blood diseases service, Rue Michel Polonowski, 59000, Lille
Centre Hospitalier Universitaire De Nantes
Hematology Department, 1 Place Alexis Ricordeau, 44000, Nantes
Centre Hospitalier Universitaire De Bordeaux
Hematology Department, Avenue De Magellan, 33600, Pessac

Germany

4 sites · Ongoing, recruitment ended
Poliklinik gGmbH Chemnitz
Klinik für Innere Medizin III, Buergerstrasse 33, Schlosschemnitz, Chemnitz
University Medical Center Hamburg-Eppendorf
II. Medizinische Klinik und Poliklinik, Martinistrasse 52, Eppendorf, Hamburg
Universitaetsklinikum Heidelberg AöR
Innere Medizin V, Haematologie, Onkologie und Rheumatologie, Im Neuenheimer Feld 410, Neuenheim, Heidelberg
Universitaetsklinikum Wuerzburg AöR
Medizinische Klinik und Poliklinik II, Oberduerrbacher Strasse 6, Grombuehl, Wuerzburg

Italy

6 sites · Ongoing, recruitment ended
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
UO Ematologia, Piazzale Spedali Civili 1, 25123, Brescia
Azienda Ospedaliero Universitaria Delle Marche
SOD Clinica Ematologica, Via Conca 71, 60126, Ancona
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
UO Ematologia, Largo Francesco Vito 1, 00168, Rome
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
UO Ematologia, Piazza Oms 1, 24127, Bergamo
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
UO Oncoematologia, Via Piero Maroncelli 40, 47014, Meldola
Azienda Ospedaliero Universitaria Pisana
UO Ematologia, Via Roma 67, 56126, Pisa

Poland

7 sites · Ongoing, recruitment ended
Dolnoslaskie Centrum Onkologii Pulmonologii I Hematologii
Centrum Hematologiczno-Transplantacyjne, Ul. Grabiszynska 105, 53-439, Wroclaw
Pratia Hematologia Sp. z o.o.
Pratia Onkologia Katowice, Ul. Tadeusza Kosciuszki 92, 40-519, Katowice
Centrum Onkologii Ziemi Lubelskiej Im. Sw. Jana Z Dukli
Oddział Hematologii i Transplantacji Szpiku, Ul. Dra Kazimierza Jaczewskiego 7, 20-090, Lublin
Medical University Of Warsaw
Klinika Hematologii, Transplantologii i Chorób Wewnętrznych, Ul. Stefana Banacha 1a, 02-097, Warsaw
Wojewodzki Szpital Specjalistyczny W Bialej Podlaskiej
Oddział Hematologii, Ul. Terebelska 57/65, 21-500, Biala Podlaska
Uniwersyteckie Centrum Kliniczne
Klinika Hematologii i Transplantologii, Ul. Mariana Smoluchowskiego 17, 80-214, Gdansk
Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Kielcach
Klinika Hematologii i Transplantacji Szpiku, Ul. Prezydenta Stefana Artwinskiego 3, 25-734, Kielce

Spain

8 sites · Ongoing, recruitment ended
Hospital Clinic De Barcelona
Hematology, Calle Villarroel 170, 08036, Barcelona
Hospital Universitario Marques De Valdecilla
Hematology, Avenida Valdecilla Sn, 39008, Santander
Hospital Universitario Fundacion Jimenez Diaz
Hematology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Institut Catala D'oncologia
Hematology, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Hospital Universitario 12 De Octubre
Hematology, Bloque D, Avenida De Cordoba Sn, Madrid
Clinica Universidad De Navarra
Hematology, Avenue Pio XII 36, 31008, Pamplona
Hospital Universitario Quironsalud Madrid
Hematology, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon
Hospital Universitario De Salamanca
Hematology, Paseo De San Vicente 58-182, 37007, Salamanca

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-06-03 2024-07-16 2025-03-03
Germany 2024-06-04 2024-08-06 2025-03-03
Italy 2024-06-05 2024-07-27 2025-03-03
Poland 2024-06-10 2024-07-22 2025-03-03
Spain 2024-06-10 2024-07-08 2025-03-03

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-09 France Acceptable
2024-06-03
2024-06-03
2 SUBSTANTIAL MODIFICATION SM-1 2024-11-18 France Acceptable
2025-02-19
2025-02-19
3 SUBSTANTIAL MODIFICATION SM-2 2025-11-07 France Acceptable
2026-02-02
2026-02-02